Company Overview of QIAGEN Hannover GmbH
QIAGEN Hannover GmbH, a biotechnology research and development company, develops tumor diagnostics for the detection and molecular analysis of tumor cells. The company’s proprietary test system (Combination-of-Combinations-Principle) that is based on reverse transcriptase-polymerase chain reaction detects circulating tumor cells in the blood of tumor patients. It markets its kits for the research of breast and colon cancer in Europe. QIAGEN Hannover GmbH was formerly known as AdnaGen AG. The company was founded in 1999 and is based in Langenhagen, Germany. As of October 28, 2010, QIAGEN Hannover GmbH operates as a subsidiary of Alere Holdings Bermuda Limited.
Founded in 1999
49 511 72595050
49 511 72595040
Key Executives for QIAGEN Hannover GmbH
Similar Private Companies By Industry
|4 Animals AlsterScience GmbH||Europe|
|Acousia Therapeutics GmbH||Europe|
|Across Barriers GmbH||Europe|
|Actinodrug Pharmaceuticals GmbH||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact QIAGEN Hannover GmbH, please visit www.adnagen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.